September 4-7 2018
Boston, MA

Twitter logo for website footers 2

2017 Post Summit Deep Dive Day

Friday September 8th 2017

In order to drill down on the most crucial topics plaguing CAR-TCR development, we are offering a wide variety of deep dive sessions. These 2 hour sessions provide an enhanced learning experience and are a more intimate opportunity to not only learn from experts on key topic areas, but also to interact with them in a frank, open and peer level environment.

Session J: 9.00 – 11.00am

Regional CAR-T Therapy for Improving Directionality of Cells for Solid Tumor

Steven Katz, Director of Surgical Immunotherapy, Roger Williams Cancer Center

Session K: 9.00 – 11.00am

Autologous vs Allogeneic: How Can We Make Allogeneic Therapies a Reality

David Sourdive, EVP, Corporate Development, Cellectis
 11.00 – 12.00pm Morning Debrief

Session M: 12.00 – 2.00pm

Mechanisms to Control CAR-T Cells: Towards a Safer Therapy

Travis Young, Principal Investigator, CALIBR

Session O: 12.00 – 2.00pm

Delivering Automated Solutions for CAR-T Cell Manufacturing: A Case Study

Rodney Rietze, Lead, cGMP Process Automation, Novartis

Session P: 2.00 – 4.00pm

Novel Gene Editing Approaches to Improve Efficacy
of CAR-TCR Therapies

Isabelle Rivière, Director, Michael G. Harris Cell Therapy & Cell Engineering Facility, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center
Jorge Mansilla-Soto, Senior Scientist, Memorial Sloan Kettering Cancer Center
David Sourdive, EVP, Corporate Development, Cellectis

Session Q: 2.00 – 4.00pm

Designer Manufacturing Facilities for Designer T Cells

Bruce Levine, Director, Clinical Cell and Vaccine Production
Facility, Perelman School of Medicine and Abramson Cancer Center, University of Pennsylvania
4.00 – 5.00pm Evening Debrief

Sessions L, N and R have been canceled. If you were registered to attend these please send an email to to change your selections.

Download the Full Program to see full details on these sessions.